IOVA · Iovance Biotherapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $9.79
Note written ·
Price against the kill line
20.7% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $9.79, on record since 11 November 2026. The shares are up 9.3% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $9.79, well over the 11 November 2026 close of $8.09, which would show the shares leading the S&P 500. Full-year 2026 revenue above the $420 million top of guidance would also prove the call wrong.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 5 November 2026; valuation at the 13 November 2026 close
- Revenue, latest quarter ($M)
- 122
- Revenue, change on a year (%)
- +80.1
- Gross margin (%)
- 60.5
- Operating margin (%)
- −19.7
- Free cash flow, four quarters ($M)
- −216
- Net cash, cash less debt ($M)
- 312
- Enterprise value to sales (×)
- 8.6
- Free-cash-flow yield (%)
- −6.0
All filed numbers
What Iovance Biotherapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Quarter to | Revenue ($M) | On a year (%) | Gross margin (%) | Operating margin (%) |
|---|---|---|---|---|
| first filed | 122 | +80.1 | 60.5 | −19.7 |
| first filed | 99.3 | +65.7 | 56.1 | −52.3 |
| first filed | 71.4 | +44.8 | 40.5 | −113.5 |
| first filed | 86.8 | +17.7 | 50.3 | −84.7 |
| first filed | 67.5 | +15.2 | 43.0 | −140.7 |
| first filed restated | 60.0 | +92.7 | 18.5 | −189.8 |
| Pre-tax income ($M) | −21.7 |
| Net income ($M) four quarters: −221 | −22.3 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +25.2 |
| Operating cash flow ($M) | −190 |
| Capital spending ($M) | 26.1 |
| Free cash flow ($M) | −216 |
| Cash and short-term investments ($M) | 376 |
| Debt ($M) at 31 March 2026, filed 7 May 2026; notes | 1.0 |
| Net cash, cash less debt ($M) at 31 March 2026, filed 7 May 2026 | 312 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | 107 |
| Inventory ($M) | 55.2 |
| Shareholders' equity ($M) | 813 |
| Market value ($M) | 3,590 |
| Enterprise value, market value plus net debt ($M) | 3,278 |
| Enterprise value to sales (×) | 8.6 |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 4.4 |
| Free-cash-flow yield (%) | −6.0 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 12.7% of shares outstanding sold short, 4.4 days of average trading to cover, −9.1% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $0 |
| 12 monthsfrom | $0 | $0 |
The thesis
Iovance Biotherapeutics' shares are more likely to lag the S&P 500 than lead it over the next three months. Third-quarter Amtagvi sales beat estimates on 5 November 2026, yet the shares fell 11% that session. The lung expansion case now depends on a biomarker-selected subgroup that has not yet been tested in a prospective trial. Full-year 2026 revenue against the $410–420 million guidance range is the next test, and the fourth-quarter report is where it is decided.
The rating is Low because the market sold a clean revenue beat. The company's 5 November 2026 release reported total revenue of about $121.5 million, up 80% from $67.5 million a year earlier, with US Amtagvi revenue of about $102 million. The company only reaffirmed the $410–420 million range after nine-month revenue of $292.2 million. The shares closed at $8.70 on 4 November 2026 and at $7.74 on 5 November 2026.
At the 11 November 2026 close of $8.09, the shares sit 47.4% below the 21 October 2026 intraday high of $15.37 and below the 50-day moving average of $11.37. The price has dropped the premium for a broad lung launch. The fall on 5 November 2026 shows that faster Amtagvi sales alone did not lift it.
Bullish and bearish views on Iovance Biotherapeutics, Inc.
The bull case on Iovance Biotherapeutics, Inc. (IOVA), in brief: third-quarter revenue beat consensus. The bear case: shares fell on a beat.
Bull case
- Third-quarter revenue beat consensus. Zacks reported on 6 November 2026 that revenue of $121.5 million beat the $117.7 million consensus. US Amtagvi revenue of about $102 million rose 77% from a year earlier and 12% from the second quarter.
- Margins widened and losses shrank. Gross margin excluding depreciation and amortization reached about 60% in the third quarter, up from 56% in the second, per the 5 November 2026 release. The net loss was $22.3 million, against $91.3 million a year earlier. Zacks put research and development spending at $49.3 million, down 34.4% from a year earlier.
- Cash runway moved into 2029. Cash, investments and restricted cash totalled about $382 million at 30 September 2026. The company now says this funds operations "well into 2029". At the second-quarter report it said "into the second half of 2028".
- Two price targets rose after the report. Barclays kept an Overweight rating and raised its target to $19 on 6 November 2026. Citizens kept Market Outperform and raised its target to $12 the same day.
- Clinical programmes still have a path. In a retrospectively identified lung subgroup with no KRAS or HER2 mutations and a smoking history, 13 of 22 patients (59.1%) responded, per the 29 October 2026 update. The 80-patient POSITILITY cohort starts enrolling in November 2026. Final frontline melanoma data on 23 October 2026 showed a 62.5% confirmed response rate (15 of 24).
Bear case
- Shares fell on a beat. The close went from $8.70 on 4 November 2026 to $7.74 on 5 November 2026. Zacks reported that Proleukin revenue of about $20 million came in below the $22 million consensus. The company kept the full-year range rather than raising it.
- Broad lung benefit did not show. The 29 October 2026 IOV-LUN-202 update gave a 24.6% objective response rate (17 of 69), against 25.6% (10 of 39) at the prior update. KRAS-mutant patients responded at 11.4% (4 of 35). StockTwits reported that the shares were headed for their worst day in more than 17 months on that update.
- The share count has grown. Weighted average shares were 455.9 million in the third quarter, against 364.0 million a year earlier, per the 5 November 2026 release. Cash rose from about $304 million at 30 June 2026 to about $382 million at 30 September 2026 while the company reported a quarterly net loss. That points to share sales, most likely under the $350 million at-the-market programme Zacks reported in August 2025.
- A securities investigation is open. Pomerantz LLP said on 6 November 2026 that it is investigating potential securities claims on behalf of Iovance investors. This followed the gap between the 28 October 2026 announcement of "positive data" and the lung results presented the next day.
- Leadership is still interim. The 5 November 2026 release quotes Frederick Vogt as Interim Chief Executive Officer and President.
Price setup
The shares closed at $8.09 on 11 November 2026. Closes in the five sessions after the report have held between $7.74 (5 November 2026) and $8.17 (9 November 2026). The session before the report closed at $8.70 on 4 November 2026.
The 50-day moving average of $11.37 sits above the price, reflecting the late-October peak. The 200-day moving average of $6.06 sits below it. The 52-week intraday high is $15.37, set on 21 October 2026, and the 52-week closing low is $2.13, set on 2 December 2025. Over three months the shares are up 24.1% from the $6.52 close on 13 August 2026.
The case turns on whether the shares can recover toward the 50-day average without a new clinical or revenue catalyst. The next scheduled revenue figure is the fourth-quarter report, and the next clinical milestones are POSITILITY enrollment and the first-quarter 2027 UK regulatory decision.
Catalysts ahead
- ~November 2026 (est.): POSITILITY biomarker-selected lung cohort begins enrolling. It is the prospective test of the 59.1% subgroup response rate that now carries the lung expansion case.
- ~February 2027 (est.): Q4 and full-year 2026 results. Shows whether full-year revenue lands inside or above the $410–420 million range and whether gross margin keeps rising from about 60%.
- ~March 2027 (est.): Potential UK (MHRA) and Swiss approvals of lifileucel. The company guides to these in the first quarter of 2027; approval would add the first sales outside North America and Australia.
- ~2027 (est.): Planned supplemental filing in non-squamous metastatic NSCLC. Its scope shows whether lung adds a broad market or a biomarker-defined niche to Amtagvi sales.
What would change the view
A daily close above $9.79, well over the 11 November 2026 close of $8.09, which would show the shares leading the S&P 500. Full-year 2026 revenue above the $420 million top of guidance would also prove the call wrong.
What it trades with
Iovance trades mostly on its own news. The 29 October 2026 fall followed a company trial update, and the 5 November 2026 fall followed its own report. Zacks partly linked the 5 November 2026 decline to broad market weakness after the US midterm elections. Commercial-stage cell therapy and immuno-oncology names are the closest peers. Small- and mid-cap biotech indices are a secondary influence, because the company still reports losses and has an at-the-market share programme.
The evidence, claim by claim (8)
- Q3 2026 total revenue was about $121.5 million, up 80% from $67.5 million in Q3 2025; US Amtagvi revenue was about $102 million (+77% year on year, +12% sequentially) and global Proleukin about $20 million. Iovance 8-K Exhibit 99.1, 5 November 2026 · as of
- Q3 2026 gross margin excluding depreciation and amortization was about 60% versus 56% in Q2 2026; net loss was $22.3 million versus $91.3 million in Q3 2025. Iovance 8-K Exhibit 99.1, 5 November 2026 · as of
- Cash, investments and restricted cash totalled about $382 million at 30 September 2026, which the company expects to fund operations well into 2029; weighted average shares were 455.9 million versus 364.0 million a year earlier. Iovance 8-K Exhibit 99.1, 5 November 2026 · as of
- Iovance reaffirmed FY2026 total revenue guidance of $410–420 million after nine-month revenue of $292.2 million. Iovance 8-K Exhibit 99.1, 5 November 2026 · as of
- Q3 2026 revenue of $121.5 million beat the $117.7 million consensus; Proleukin revenue of about $20 million missed the $22 million consensus. Zacks via Yahoo Finance, 6 November 2026 · as of
- Barclays kept an Overweight rating and raised its target to $19; Citizens kept Market Outperform and raised its target to $12. Analyst notes reported 6 November 2026 · as of
- Updated IOV-LUN-202 results showed a 24.6% objective response rate (17 of 69) in previously treated non-squamous metastatic NSCLC; KRAS-mutant patients responded at 11.4% (4 of 35). Iovance press release, 29 October 2026 · as of
- The biomarker-enriched POSITILITY registrational cohort begins enrolling in November 2026 with a target of 80 patients; Iovance has more than 100 authorized treatment centres and expects at least 110 by end-2026. Iovance 8-K Exhibit 99.1, 5 November 2026 · as of
Sources
- IOVANCE BIOTHERAPEUTICS, INC. - Form 8-K - FY2026 · sec.gov ·
- IOVA Q3 Earnings Beat on Amtagvi Sales and Lower R&D Costs · finance.yahoo.com ·
- Finviz
- Iovance Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026 · marketscreener.com
- IOVA Stock Heads For Worst Day In Over 17 Months, Retail Says 'Selling Is Not Done' – What's Driving The Fall? · stocktwits.com
Related · shared themes
ORKA
Oruka Therapeutics
Oruka Therapeutics is modestly more likely to beat the S&P 500 over three months: its psoriasis antibody ORKA-001 cleared skin completely…
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
XNCR
Xencor
Xencor's shares hold a modest edge over the S&P 500 on XmAb819's 45.5% confirmed response rate in advanced kidney cancer and cash funding…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
See also · stocks to watch